Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
出版年份 2022 全文链接
标题
Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
作者
关键词
-
出版物
Gastric Cancer
Volume 25, Issue 4, Pages 741-750
出版商
Springer Science and Business Media LLC
发表日期
2022-06-05
DOI
10.1007/s10120-022-01301-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer
- (2021) Ming Lei et al. CLINICAL CANCER RESEARCH
- PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy
- (2021) Soomin Ahn et al. MODERN PATHOLOGY
- Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19
- (2021) Chun Chau Lawrence Cheung et al. GUT
- Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
- (2021) Jong-Mu Sun et al. LANCET
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
- (2021) Yelena Y Janjigian et al. LANCET
- Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma
- (2021) Joseph J. Zhao et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC
- (2020) Joe Yeong et al. JOURNAL OF CLINICAL PATHOLOGY
- The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
- (2020) Janis M Taube et al. Journal for ImmunoTherapy of Cancer
- Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization
- (2020) Matthew P. Humphries et al. Cancers
- Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
- (2020) Kohei Shitara et al. JAMA Oncology
- Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination
- (2020) Raghav Sundar et al. GUT
- KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
- (2019) Ken Kato et al. Future Oncology
- PD-L1 expression in gastroesophageal dysplastic lesions
- (2019) Matteo Fassan et al. VIRCHOWS ARCHIV
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET
- An automated staining protocol for seven-colour immunofluorescence of human tissue sections for diagnostic and prognostic use
- (2018) Jeffrey Chun Tatt Lim et al. PATHOLOGY
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Tissue microarrays – translational biomarker research in the fast lane
- (2018) Felix Behling et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1
- (2018) Lola Fashoyin‐Aje et al. ONCOLOGIST
- PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability
- (2017) Hans Brunnström et al. MODERN PATHOLOGY
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
- (2017) David L. Rimm et al. JAMA Oncology
- cellXpress: a fast and user-friendly software platform for profiling cellular phenotypes
- (2013) Danai Laksameethanasan et al. BMC BIOINFORMATICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now